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In immunocompromised patients, inﬂ  uenza  infection 
may progress to prolonged viral shedding from the respi-
ratory tract despite antiviral therapy.  We describe chronic 
inﬂ  uenza A virus infection in an immunocompromised child 
who had prolonged shedding of culturable inﬂ  uenza virus 
in stool.
H
uman inﬂ  uenza A virus infections are typically lo-
calized to the respiratory tract, and viral presence in 
the gastrointestinal (GI) tract is rarely observed. Isolation 
of inﬂ  uenza virus from the stool is most commonly docu-
mented in human infections of avian inﬂ  uenza  subtype 
H5N1. In these infections, virus in the stool may be related 
to a disseminated infection with exceptionally high viral 
titers, atypical of seasonal, circulating inﬂ  uenza infections 
(1). Interestingly, infections with the inﬂ  uenza A pandemic 
(H1N1) 2009 virus can be associated with a high rate of GI 
symptoms (2). Although seasonal inﬂ  uenza RNA in stool 
has been described, we report here the culturing of H1 virus 
from stool. 
Case Report
The patient was a 4.5-year-old boy who had received 
a bone marrow transplant for Wiskott-Aldrich syndrome 
4 years earlier; he also had chronic graft versus host dis-
ease of the GI tract. In January 2008, fever and respiratory 
symptoms developed in the patient, and direct ﬂ  uorescent 
antibody (DFA) testing of a nasopharyngeal swab speci-
men showed inﬂ  uenza A infection. Over the next several 
months, he had additional inﬂ  uenza A–positive DFAs and 
was given oral and aerosolized ribavirin for chronic infec-
tion. Despite this aggressive antiviral treatment, >24 respi-
ratory specimens were positive for inﬂ  uenza A by DFA or 
culture over the next year.
When the patient was ≈3 months into an extended hos-
pitalization at the Lucile Packard Children’s Hospital (com-
plicated by pseudomonal and enterococcal bacteremia, as 
well as disseminated aspergillosis), he experienced multiple 
daily episodes of nonbilious, nonbloody emesis (≈2–3/day) 
and loose stools without blood or mucous (up to 12/day). 
The clinical team suspected a graft versus host disease ﬂ  are 
but also conducted a work up of the patient to identify an 
infectious process. Results of blood cultures, stool culture, 
Clostridium difﬁ  cile–toxin B cytotoxicity assay, and stool 
examination for ova and parasites were all negative. Results 
of a urine culture were positive for enterococcus. Culture of 
stool samples was enterovirus positive and over the subse-
quent 2 weeks, enterovirus was isolated from 2 additional 
viral stool cultures. These cultures were not evaluated for 
the presence of inﬂ  uenza virus. Three weeks after the initial 
stool testing, results of viral stool culture and repeat stool 
studies were negative. However, the diarrhea and emesis 
persisted, and ≈8 weeks after the onset of symptoms, an-
other stool specimen was sent for viral culture.
After 3 days, the culture demonstrated cytopathic ef-
fect on primary RhMK cells but not on human foreskin 
ﬁ  broblasts, MRC-5 ﬁ  broblasts, or A549 lung carcinoma 
cells, which is consistent with enterovirus infection. How-
ever, results of immunoﬂ  uorescent staining of the RhMK 
cells (by using a panenterovirus blend of monoclonal anti-
bodies) were negative. Staining results were also negative 
with serotype group–speciﬁ  c reagents, including the cox-
sackie virus B blend, echovirus blend, enterovirus 70 and 
71, poliovirus blend, coxsackie virus A9, and coxsackie 
virus A24 (all enterovirus reagents from Millipore/Light 
Diagnostics, Billerica, MA, USA).  An astute technologist 
associated the pattern of cells showing a cytopathic effect 
with the patient’s concurrent inﬂ  uenza A–positive respira-
tory specimen and long history of inﬂ  uenza infection. She 
then set up a standard respiratory virus DFA panel (Mil-
lipore/Light Diagnostics), which included ﬂ  uorescein-con-
jugated antibodies for the detection of inﬂ  uenza A and B; 
respiratory syncytial virus; parainﬂ  uenza 1, 2, and 3; and 
adenovirus. Strikingly, the specimen was strongly positive 
for inﬂ  uenza A virus and showed obvious hemadsorption 
with guinea pig erythrocytes.  Two months later, inﬂ  uenza 
A was again isolated from the patient’s stool, which sug-
gested persistent infection of the GI tract with inﬂ  uenza 
A virus. Subsequent nucleic acid testing revealed that this 
chronic inﬂ  uenza A infection was caused by the seasonal, 
circulating subtype H1N1 virus. Overall, the patient shed 
inﬂ  uenza A from respiratory secretions for >1.5 years and 
from stool for >2 months.
Conclusions
Because viral stool cultures from patients with respi-
ratory infections are infrequently ordered, the true occur-
rence of inﬂ  uenza virus in stool is unknown. The few stud-
ies to date have considered viral RNA in fecal specimens 
as a marker of GI inﬂ  uenza infection, which may not ac-
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for transmission. One study of 4 children with respiratory 
symptoms and conﬁ  rmed inﬂ  uenza infection showed that 
half had inﬂ  uenza RNA in stool (3). In contrast, 6 (<1%) 
of 627 patients with GI symptoms had detectable inﬂ  uenza 
RNA in fecal samples (4). Similarly, inﬂ  uenza RNA was 
detected in 21 (2.9%) stool samples from 733 children in 
Indonesia who had concurrent diarrhea and inﬂ  uenzalike 
illness (5). Notably, in this study, culturable inﬂ  uenza B 
virus was isolated from the stool of 1 patient. Future studies 
will be required to ascertain the incidence of inﬂ  uenza virus 
in the stool of children and adults with inﬂ  uenzalike illness 
and respiratory inﬂ  uenza infection. Furthermore, given the 
importance of this issue for infection control and the lim-
ited number of laboratories that perform stool viral culture, 
additional work will be necessary to correlate inﬂ  uenza 
RNA in feces with the presence of infectious virus.
The lack of a fully intact immune system likely predis-
posed our patient to chronic inﬂ  uenza infection and spread 
of the virus to the GI tract. This patient had received a bone 
marrow transplant for primary immunodeﬁ  ciency as well 
as immunosuppressive therapy for graft versus host dis-
ease with methylprednisolone, tacrolimus, sirolimus, and 
daclizumab. Prolonged viral shedding from the respiratory 
tract and the development of antiviral resistance is well 
documented in immunocompromised patients, including 
patients who have received bone marrow transplants (6). 
Although bone marrow transplant patients appear more sus-
ceptible to lower respiratory tract disease, in particular, dur-
ing inﬂ  uenza outbreaks (7), inﬂ  uenza virus in stool samples 
from this patient population has not been well studied. No-
tably, our patient was not treated with either of the common 
classes of anti-inﬂ  uenza drugs, the neuraminidase inhibi-
tors or adamantanes, but rather received a long-term course 
of ribavirin. Although clinical cases of ribavirin-resistant 
inﬂ  uenza virus infection have not yet been reported, geno-
typic and phenotypic analysis of this patient’s isolate may 
show resistance or other virus-speciﬁ  c factors associated 
with chronic inﬂ  uenza and the presence of virus in stool. 
Although culturable inﬂ  uenza A virus was isolated from 
the stool of our patient, whether it played a causative role in 
the patient’s gastroenteritis could not be determined.
While inﬂ  uenza virus likely spread to the patient’s GI 
tract after a primary respiratory infection, the route of dis-
semination remains unknown. One possibility is direct GI 
inoculation by swallowing respiratory secretions. Because 
inﬂ  uenza viruses enter the cell through acid-activated fu-
sion with the endosomal membrane (8), a low pH envi-
ronment, for example in the human stomach, is thought to 
render most inﬂ  uenza viruses noninfectious by prematurely 
inducing an irreversible conformational change in the viral 
hemagglutinin (9). However, the sensitivity of inﬂ  uenza vi-
rus to low pH inactivation appears dependent on strain and 
subtype (10). Our patient was on a proton pump inhibitor, 
which would reduce gastric acidity.  Another possibility is 
that the virus reached the GI tract hematogenously, as is 
suspected in human cases of avian inﬂ  uenza (1).
Whether the inﬂ  uenza subtype that infected this patient 
is capable of local GI replication in humans is also unclear. 
In the GI tract, the virus likely encountered the proteases 
necessary for hemagglutinin cleavage and activation (11). 
However, the H1 hemagglutinin has relative speciﬁ  city for 
α 2,6-linked sialic acid, a cell-surface glyco-conjugate not 
normally found on mucosa of the colon or small intestine 
(12,13). Nevertheless, this binding speciﬁ  city is not ab-
solute (14), and 2,3-linked sialic acids are abundantly ex-
pressed on colorectal epithelial cells (13). Future studies 
should assess the ability of inﬂ  uenza viruses to replicate in 
the human intestinal epithelium.
Early epidemiologic study of the pandemic (H1N1) 
2009 virus suggested that it produced diarrhea, vomiting, 
or both, in ≈25% of case-patients, more often than the pre-
vious seasonal, circulating inﬂ  uenza viruses (2). Consistent 
with the GI symptoms of human infection, experimental 
respiratory inoculation of ferrets with human isolates of the 
pandemic strain results in high inﬂ  uenza virus titers in the 
intestinal tract of infected animals (15). Because knowledge 
of transmission of this novel virus is limited, the Centers 
for Disease Control and Prevention recommends that all 
bodily ﬂ  uids, including the diarrheal stool of infected per-
sons, be assumed to be infectious and handled with precau-
tions. With the emergence of this pandemic (H1N1) 2009 
strain known to produce GI symptoms, further research ad-
dressing the presence of inﬂ  uenza virus in stool could have 
major consequences for both infection control and disease 
management.
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